News

Byrna Technologies Inc. Reports Exciting Q1 2025 Results

Byrna Technologies Inc. Reports Exciting Q1 2025 Results

Overview of Byrna Technologies' Fiscal Q1 2025 Results

Byrna Technologies Inc. (“Byrna” or the “Company”) (NASDAQ: BYRN), a leader in personal defense technology, has released its financial results for the fiscal first quarter of 2025, which ended on February 28, 2025. This quarter highlights Byrna's ongoing commitment to innovation and growth in the less-lethal personal security solutions market.

Operational Achievements

Store Expansion Initiatives

This quarter marked the launch of Byrna’s inaugural store-within-a-store at Sportsman’s Warehouse flagship outlet, aiming to enhance customer experience and accessibility. With 12 additional stores set to open soon, Byrna is excited about its retail expansion strategy.

Retail Performance

Byrna successfully opened three new company-owned retail locations in high-traffic areas, generating impressive daily sales figures of $1,000 to $1,700 each in their first month. A fourth location is set to launch, showcasing Byrna's strategy of strategic retail placement to capture diverse customer bases.

Financial Highlights

The financial results for Q1 reflect Byrna's robust growth trajectory:

  • Net Revenue: The Company saw a remarkable 57% year-over-year increase, with net revenue reaching $26.2 million, an impressive leap from the $16.7 million reported in Q1 2024.
  • Gross Profit: Byrna achieved a gross profit of $15.9 million, accounting for 61% of net revenue. This improvement is credited to effective cost management and increased production volume.
  • Operating Expenses: Operating expenses rose to $14.2 million, attributed mainly to elevated hiring costs and marketing efforts necessary to drive growth.
  • Net Income: A net income of $1.7 million was recorded for Q1 2025, showcasing substantial growth from a mere $17,000 during the same period last year.

Strategic Outlook

Future Growth Plans

Byrna’s CEO, Bryan Ganz, emphasized the significance of this quarter's strong financial results, affirming a consistent sales momentum across its product lines. The upcoming launch of the Compact Launcher is anticipated to further bolster sales and enhance brand visibility.

Manufacturing Capabilities

To cater to increasing demand, Byrna has ramped up monthly production capacity to 24,000 launchers. The establishment of a new ammunition facility signifies Byrna’s commitment to self-sufficiency, enabling the production of up to 8 million rounds annually.

Commitment to Excellence

Byrna is focused on increasing the domestic sourcing of components, achieving a remarkable 92% U.S.-made content for its flagship product. The Company is committed to its ‘Made in America’ initiative, reinforcing its dedication to quality and supporting the domestic economy.

Investor Communication

In conjunction with the release of these results, Byrna management will host a conference call to offer deeper insights into the quarter's performance and address investor inquiries. Call-in details are provided for all interested parties.

Frequently Asked Questions

What are Byrna Technologies' main products?

Byrna Technologies specializes in the development and sale of innovative, less-lethal personal security devices aimed at providing safety solutions for consumers and law enforcement.

When was Byrna's fiscal first quarter?

The fiscal first quarter for Byrna Technologies ended on February 28, 2025.

How did Byrna perform compared to last year?

Byrna experienced a 57% increase in net revenue compared to Q1 of the previous year, showcasing strong growth and market acceptance.

What new initiatives did Byrna launch this quarter?

This quarter, Byrna launched its store-within-a-store partnership at Sportsman’s Warehouse, expanding retail presence to enhance customer access to their products.

What is Byrna's commitment to manufacturing?

Byrna is committed to U.S. manufacturing, aiming for over 90% of its products to be sourced domestically by the end of 2025, enhancing supply chain reliability.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

Paulex Bio's PAL-119 Trials: A New Diabetes Frontier

Updated Category News Views 80

Chasing the Holy Grail in Diabetes Treatment The pursuit of a true remedy for diabetes is almost like hunting for the mythical beast—a challenge that's left plenty of contenders biting the dust over the years. Yet, here's Paulex Bio jumping right into the fray with their groundbreaking PAL-119. They're not just peddling another temporary fix like most on the market;...

Continue Reading
PRG Projects' London Studio Elevates Live Entertainment

Updated Category News Views 172

A New Stage for Creativity in London When the curtain rises on a fresh idea, it's often the unknowns that make or break a production. Now, with PRG Projects unveiling their spanking new Project Studio in London, the tech and creative worlds might just bridge their gap tighter than a stage curtain before showtime. London Welcomes PRG's Innovative Hub This isn't just...

Continue Reading
TriMas Streamlines Portfolio with Rapak Sale

Updated Category News Views 48

TriMas Sheds Rapak: A Strategic Move Here's a twist worth dissecting: TriMas Corporation (NASDAQ: TRS) has offloaded its subsidiary Rapak, LLC to the German industrial packaging giant, Ringmetall SE. This isn't just a business shuffle—it's a calculated pivot with eyes on sharpening the core business blade. As they announced from Bloomfield Hills, Michigan, this move...

Continue Reading
i-80 Gold's Q3 2026: Production Plans Unveiled

Updated Category News Views 31

Gold Miners on the Move: Eye on i-80 Wake up and smell the gold, folks. i-80 Gold is ramping up to increase its yearly gold production targets, aiming for a hefty 150,000 to 200,000 ounces by 2028. Now, if you’ve been around the block like me, you know these are the kind of numbers that get investors either shifting in their chairs or springing to their feet. A Brief...

Continue Reading
RD Technologies Ramps Up Cross-Border Payments

Updated Category News Views 185

RD Technologies: Revving Up the Payment Game RD Technologies is at it again, jazzing up its game in the cross-border payments realm. One can almost smell the digits doing a tango across continents—particularly as Hong Kong's financial warriors set their sights on beefing up trade between Africa and Asia. New Alliances in the Payment Arena Here's a roadmap: Connect the...

Continue Reading
Ascletis Showcases Bold Moves in Obesity Drug Arena

Updated Category News Views 163

If you’ve been watching the developments in the world of obesity treatments, Ascletis Pharma is a name you'd do well not to ignore. With ObesityWeek 2026 on the horizon, these folks aren’t just talking—they’re putting their preclinical cards on the table and they’re noteworthy. Unveiling Future Contenders Ascletis is gearing up to present some of their...

Continue Reading
Lincoln Avenue's Bold New Move: Affordable Senior Living

Updated Category News Views 33

A New Senior Housing Era Begins in Channahon If there's one thing the affordable housing game loves, it's the mix of ambition and grit—both of which Lincoln Avenue Communities (LAC) brings to the table with The Talia. This latest project in Channahon, Illinois, marks their fourth groundbreaking in the state, cementing LAC's place as a key player in providing quality...

Continue Reading
Kim Dunbar Sheds Light on Online Personalized Learning

Updated Category News Views 11

Picture a classroom without walls, the teacher always available, and students moving at their own pace. Sounds utopian, right? Well, Virtual Public School Expert Kim Dunbar is making sense of this approach at SC Whitmore School in Columbia, South Carolina, as she explains how this works in an online high school. Mastery-Based Learning: Beyond the Conventional Rigid...

Continue Reading
Neurocrine Biosciences Hits $1 Billion Mark in Q3 2026

Updated Category News Views 23

Neurocrine's Triple-Digit Surge Neurocrine Biosciences is on a tear, pushing its revenue up to a jaw-dropping $1.1 billion in Q3 2026—a hefty 41% leap from the previous year. Frankly, you can't ignore those numbers. INGREZZA, which is practically becoming a cash cow, did $801 million alone, rising 17% year over year. This rides the wave of prescription surges and solid...

Continue Reading
Dr. Huang's Honorary Degree Caps Global Impact Journey

Updated Category News Views 41

Recognition from Alma Mater Puts a Bow on a Storied Career When someone ventures out into the world and leaves a mark across continents, it’s a remarkable feat. It’s even more heartening when the place that helped shape them gets to extend a nod of recognition. Dr. Charles Huang, the mastermind behind Pasaca Capital, just unwound a new layer to his multicolored life...

Continue Reading
/neurocrine-biosciences-hits-1-billion-mark-in-q3-2026-540185-/" title="Neurocrine Biosciences Hits $1 Billion Mark in Q3 2026 - Continue Reading" aria-label="Continue reading: Neurocrine Biosciences Hits $1 Billion Mark in Q3 2026"> Continue Reading